Argenx scraps Sjogren's trial after futility review
Argenx unexpectedly ended a Vyvgart study in Sjogren's disease after an independent monitoring committee said the trial appeared futile. Shares fell 11.8% to 818.63 in morning trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Argenx scraps Vyvgart Sjogren's study after futile review
Argenx unexpectedly ended a Vyvgart study in patients with Sjogren's disease after an independent monitoring committee said the trial appeared futile. The stock fell almost 14% in morning trading.